Table. 1—

Baseline characteristics of the patient populations

Population under studyHistorical control groupp-value
Subjects n12384
Female/male90/33 (73.2/26.8)57/27 (67.9/32.1)0.41
Age yrs52±1444±13<0.001
 IPAH89 (72)67 (80)0.23#
 PAH-CTD15 (12.2)5 (6.0)
 PAH-CHD5 (6.5)3 (3.6)
 PAH-HIV2 (1.6)2 (3.6)
 PPHT12 (9.8)7 (8.3)
Functional NYHA class III/IV98/25 (79.7/20.3)66/18 (78.6/21.4)0.85
History of syncope26 (21.1)16 (19.0)0.71
History of right heart failure35 (28.5)22 (26.2)0.72
6-min walk distance m308±133314±1250.97
Peak VO2 mL·min−1·kg−112.1±3.5NANA
Baseline haemodynamics
 RAP mmHg8±58±50.81
 PAPm mmHg52±1055±130.15
 PCWP mmHg7±38±20.30
 CO L·min−13.9±1.23.7±1.20.34
 CI L·min−1·m−22.1±0.62.1±0.60.44
 PVR dyn·s·cm−51027±4431122±4650.10
Sv,O2 %61±961±100.88
Concomitant medication
 Oral anticoagulants107 (88.0)75 (89.3)0.62
 Diuretics102 (82.9)72 (85.7)0.59
 Digitalis23 (18.7)18 (21.4)0.63
Probability of survival
 1 yr0.71±0.100.70±0.100.93
 2 yrs0.59±0.120.58±0.120.87
 3 yrs0.50±0.140.49±0.140.87
  • Data are presented as n (%) or mean±sd. The time period for the population under study was between January 1 2002 and December 31 2004. The time period for the historical control group was between January 1 1999 and December 31 2001. IPAH: idiopathic pulmonary arterial hypertension; PAH-CTD: pulmonary arterial hypertension associated with connective tissue disease; PAH-CHD: pulmonary arterial hypertension associated with congenital heart disease; PAH-HIV: pulmonary arterial hypertension associated with human immunodeficiency virus infection; PPHT: portopulmonary hypertension; NYHA: New York Heart Association; peak VO2: peak oxygen uptake determined by cardiopulmonary exercise testing; RAP: right atrial pressure; PAPm: mean pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; CO: cardiac output; CI: cardiac index; PVR: pulmonary vascular resistance; Sv,O2: mixed-venous oxygen saturation; NA: not assessed. #: IPAH versus non-IPAH only; : PAH only.